Can capmatinib cure lung cancer?

Capmatinib (Capmatinib) is an oral tablet approved by the U.S. FDA for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a specific mutation (MET exon 14 skipping) detected by an FDA-approved test. Capmatinib can be used as first-time treatment or in previously treated patients. It belongs to a class of drugs called kinase inhibitors.

Capmatinib is used to treat patients with lung cancer tumors that have abnormal genes. MET exon 14 skipping is caused by changes in the gene that makes the MET (mesenchymal-epithelial transition) protein. Capmatinib blocks the activity of these proteins resulting from MET exon 14 skipping, helping to slow cancer growth.

Capmatinib does not cure lung cancer, but some people in the study saw their tumors shrink or disappear for more than a year. There is currently no cure for lung cancer, but you may be eligible for treatments that can slow tumor growth and extend your life.

Capmatinib is not currently on the market in China, and patients cannot obtain it directly from domestic hospital pharmacies for the time being. It is understood that the original version of capmatinib is marketed in Europe with the specification of 200mg*120 capsules and the price is 57,000yuan per box. The original version of capmatinib is marketed in Hong Kong, China with the specification of 200mg*60 capsules and the price is 35,000 yuan per box. In addition, capmatinibis available in various Laos versions, with specifications of 56 capsules and the prices are around 3,000-4,000 yuan. The ingredients of the generic version are the same as those of the original version, and are more cost-effective. If you have questions about capmatinib, please consult the medical consultant of Yaode.